Cell & Gene Therapy
Regulated market (fda / ema approved cell and gene therapy products) + trial participation + trade-body membership. The Kin Score Market layer reads each provider in its market: who it integrates with, how deep those integrations go, and where the market publishes its own structure. Methodology.
Where this market publishes its structure
- FDA Approved Cellular and Gene Therapy Products (fda.gov, CBER OTP) machine-readable, 54 products / 50 makers; names only (Wikidata P856 or register-name); 7 linked; one certified product per product type
- EMA medicines report xlsx (Advanced therapy = Yes) machine-readable, 36 ATMPs / 30 MAHs; names only; 2 linked; EU MAH regional entities of catalog parents left unlinked
- ClinicalTrials.gov API v2 (interventional, industry lead sponsor, cell/gene therapy intervention) machine-readable, 1,491 CGT-intervention studies / 524 sponsors; participation only; 32 linked
- ARM (Alliance for Regenerative Medicine) member directory (members.alliancerm.org) machine-readable, 453 members with website, public 'Show all' postback (no login); 60 linked by domain + name
- ARM member profiles / Members' Portal not machine-readable: portal behind login; the public directory card (name, focus, website) is what was read
Own = declares at least one integration itself; covered = visible only because an aggregator, standards body, regulator or partner contract names it; distribution-only = listed only on cloud marketplaces it sells through, a channel reported beside, never counted as its own declared integrations; undeclared = nothing we can read, so no number; declares_compatibility = providers with a `compatible` shape vote, report only (kin, 2026-10-13): never counted as own, never in depth or position.
Taxonomy how this market maps onto apis.io
Derived 2026-10-23 from the 32 providers in this market we could resolve in the catalog. The percentage is the share of those providers carrying each one; it describes the market, not the tag or industry. Tag groups have no page of their own yet, so they are listed unlinked.
| Tags | Biotechnology 88%, Life Sciences 81%, Pharmaceuticals 44%, Clinical Trials 38%, Gene Therapy 38%, Cell Therapy 31%, Healthcare 28%, Oncology 22%, Rare Disease 22% |
|---|---|
| Tag groups | Healthcare 91%, Gene Therapy 53%, Cell Therapy 31%, Rare Disease 31% |
| Industries | Biotechnology & Drug Discovery 91%, Life Sciences 81%, Pharmaceutical 53%, Healthcare 34% |
share of resolved cohort carrying it; tags >=0.20 & >=3 members (max 12, junk dropped), tag_groups >=0.20 (cooccurrence, non-cross-cutting; max 8), industries >=0.20 (max 6), areas >=0.10 (max 6; areas are keyword-matched and sparse), capabilities L1 >=0.20 (max 8); derive-market-taxonomy.py
Leaders by position (provisional)
Provisional: grouped by position, depth compared within a position only. Distribution (cloud marketplaces) and iPaaS bridges are counted beside position, never inside it. Unknown-builder listings are left out of position shares and counted here.
standard 24 · listed by a voluntary standard's own directory
| Provider | Depth | Integrations | In / out | Unknown builder | Distribution | iPaaS bridge | Mix |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | 63.3 | 7 | 0 / 7 | 0 | 0 | 0 | contract 43%, standard 57% |
| Pfizer | 61.8 | 7 | 0 / 7 | 0 | 0 | 0 | contract 43%, standard 57% |
| Celgene | 61.1 | 5 | 0 / 5 | 0 | 0 | 0 | contract 40%, standard 60% |
| Autolus | 60.7 | 6 | 0 / 6 | 0 | 0 | 0 | contract 33%, standard 67% |
| Spark Therapeutics | 60.7 | 3 | 0 / 3 | 0 | 0 | 0 | contract 33%, standard 67% |
| Novartis | 59.3 | 7 | 0 / 7 | 0 | 0 | 0 | contract 43%, standard 57% |
| Regeneron | 57.4 | 7 | 0 / 7 | 0 | 0 | 0 | contract 29%, standard 71% |
| Catalent | 56.0 | 3 | 0 / 3 | 0 | 0 | 0 | contract 33%, standard 67% |
| Arbor Biotechnologies | 51.7 | 3 | 0 / 3 | 0 | 0 | 0 | standard 100% |
| Atsena Therapeutics | 51.7 | 3 | 0 / 3 | 0 | 0 | 0 | standard 100% |
| iECURE | 51.7 | 4 | 0 / 4 | 0 | 0 | 0 | standard 100% |
| Asimov | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| CUTISS | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| Dyno | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| Kriya Therapeutics | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| Life Biosciences | 34.5 thin | 2 | 0 / 2 | 0 | 0 | 0 | standard 100% |
| A2 Biotherapeutics | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Alloplex Biotherapeutics | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Ascend Advanced Therapies | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Code Biotherapeutics | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Elegen | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Gameto | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| KSQ Therapeutics | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
| Tune Therapeutics | 17.2 thin | 1 | 0 / 1 | 0 | 0 | 0 | standard 100% |
undeclared 8 · declares nothing we can read: no number
| Provider | Depth | Integrations | In / out | Unknown builder | Distribution | iPaaS bridge | Mix |
|---|---|---|---|---|---|---|---|
| 3T Biosciences | undeclared | - | - | - | - | - | |
| AAVantgarde Bio | undeclared | - | - | - | - | - | |
| American Gene Technologies | undeclared | - | - | - | - | - | |
| Genscript Probio | undeclared | - | - | - | - | - | |
| PBS Biotech | undeclared | - | - | - | - | - | |
| Slingshot Biosciences | undeclared | - | - | - | - | - | |
| Synthego | undeclared | - | - | - | - | - | |
| Wugen | undeclared | - | - | - | - | - |
Generated 2026-10-24 from API Evangelist's own files; nothing on this page is a model's judgement. Provisional and unweighted; not part of the Kin Score composite or agent readiness. Read the Market layer methodology. Disagree with an edge? Every edge cites its evidence and can be corrected through the normal correction path.